BRAF and Lynch syndrome: BRAF mutations, particularly p.V600E, are critical prognostic biomarkers in sCRC, they are associated with adverse outcomes and helpful in excluding Lynch syndrome, given their mutual exclusivity with RAS mutations and the lack of benefit from anti-EGFR therapy for patients with BRAF p.V600E mutations [45].